Blocking Beta4 Integrin FAK Interaction for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular mechanism by which upstream receptors, including integrins and growth factor receptors, activate focal adhesion kinase (FAK) autophosphorylation and contribute to tumor malignancy in cancers such as colon cancer remains unclear, limiting the development of effective therapeutic agents.
Innovation Solution
Blocking the interaction between β4 integrin and FAK using agents like peptides, antibodies, or gene therapy to disrupt their binding, thereby inhibiting FAK-mediated signaling pathways that promote cancer progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the interaction between β4 integrin and FAK is blocked to prevent cancer progression, then tumor malignancy and metastasis are reduced, but the understanding of the molecular mechanism remains unclear
Solution Approach 1:
The patent uses peptides as intermediary molecules to block the interaction between β4 integrin and FAK. Specifically, peptides derived from the FAK binding domain of β4 integrin or peptides mimicking FAK binding sites serve as mediators that interfere with the protein-protein interaction, thereby preventing cancer progression while allowing researchers to study the mechanism through controlled experimentation
2Productivity
If FAK-mediated signaling pathways are inhibited to treat cancer, then tumor proliferation and migration are reduced, but the complexity of the signaling network increases
Solution Approach 1:
The patent extracts and targets specific critical interaction points in the FAK-mediated signaling pathway by blocking the β4 integrin-FAK binding interface. Rather than attempting to modulate the entire complex signaling network, the invention focuses on removing or blocking the key upstream interaction that triggers FAK activation, thereby simplifying the therapeutic approach while maintaining effectiveness against tumor proliferation and migration
Data Source
AI summary
The present invention is related to a method or a pharmaceutical composition for treatment or prevention of a cancer through blocking the interaction of β4 integrin and focal adhesion kinase (FAK).